- 16-9117-82 - Invitrogen Antibodies TNFRSF13C antibody

Submitted references Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves' disease.

Wang X, Huang J, Zhang A, Fang C, Ma Q, Jiang P
BMC endocrine disorders 2021 Apr 29;21(1):88

IFN-γ stimulates CpG-induced IL-10 production in B cells via p38 and JNK signalling pathways.

Imbrechts M, De Samblancx K, Fierens K, Brisse E, Vandenhaute J, Mitera T, Libert C, Smets I, Goris A, Wouters C, Matthys P
European journal of immunology 2018 Sep;48(9):1506-1521

Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy.

Hijano DR, Siefker DT, Shrestha B, Jaligama S, Vu LD, Tillman H, Finkelstein D, Saravia J, You D, Cormier SA
Scientific reports 2018 Jul 23;8(1):11034

IFN type I and II induce BAFF secretion from human decidual stromal cells.

Lundell AC, Nordström I, Andersson K, Lundqvist C, Telemo E, Nava S, Kaipe H, Rudin A
Scientific reports 2017 Jan 6;7:39904

BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R.

Zheng N, Wang D, Ming H, Zhang H, Yu X
BMC nephrology 2015 May 15;16:72

The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF).

Bornacelly A, Mercado D, Acevedo N, Caraballo L
BMC immunology 2014 Jun 7;15:22

A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.

Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N
Cancer research 2010 Jun 1;70(11):4346-56

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Staining of normal human peripheral blood cells with 0.125 µg of Mouse IgG2a K Isotype Control Functional Grade Purified (Product # 16-4724-85) (open histogram) or 0.125 µg of Anti-Human CD268 (BAFF Receptor) Functional Grade Purified (filled histogram) followed by Anti-Mouse IgG FITC (Product # 11-4011-85). Cells in the lymphocyte gate were used for analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 The expression of BAFF receptors by human mesangial cells. a Total RNA was extracted from human mesangial cells and analyzed for expression of BAFF-R, TACI, BCMA and BAFF, normalized to GAPDH expression, by real-time PCR. b The presence of BAFF-R on the surface of human mesangial cells was detected with BAFF-R antibody by flow cytometry. Background signal is presented as a gray line, and BAFF-R signal is presented as a blue line. c Cytosolic protein fraction (indicated as c) and membrane protein fraction (indicated as m) were prepared from human mesangial cells and subjected to western blot analysis. Whole protein lysate of activated human CD19 + B cells was loaded as a positive control for expression of BAFF-R. Na + /K + -ATPase and Erk kinase represented membrane and cytosolic proteins respectively

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Altered expression profile of receptors of BAFF on peripheral blood B lymphocytes in GD. a : Elevated BR3 expression on peripheral blood B lymphocytes in GD patients. Mean MFI of BR3 on peripheral B lymphocytes in GD patients was 4.52 +- 2.06, higher than that in HC (3.00 +- 0.87), P = 0.0015; BR3 expression in HT patients was not increased; b : Trend of decreased TACI expression on peripheral B lymphocytes in GD patients. Mean MFI of TACI on peripheral B lymphocytes in GD patients was 7.96 +- 4.06, lower than that in HC (9.10 +- 3.37) without significance, P = 0.1285. TACI expression in HT was not decreased. MFI: mean fluorescence intensity. Bars: mean MFI. ns: not significant; **: vs. HC, P < 0.01

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 IFN-gamma and IFN-alpha trigger BAFF production from decidual stromal cells. (a) BAFF production and relative BAFF mRNA levels to medium control by isolated decidual stromal cells in response to IFN-gamma, IFN-alpha or LPS. (b) BAFF production and relative BAFF mRNA levels to medium control by cord blood mononuclear cells in response to IFN-gamma, IFN-alpha or LPS. (c) BAFF-R expression on CD105-positive stromal cells isolated from decidua basalis or decidua parietalis after culture in the presence or absence of IFN-gamma. (d) Histograms depict podoplanin expression on stromal cells isolated from decidua basalis or decidua parietalis and the scatter plot shows the percentage of podoplanin-positive cells after stimulation with IFN-gamma or not. (e) Immunofluorescence staining of podoplanin on stromal cells isolated from decidua basalis stimulated with IFN-gamma or not (podoplanin in green and nuclei staining with Hoechst in blue). Images from one donor in the upper panel are presented with x 10 magnification and images from a second donor in the lower panel are presented with x 25 magnification (scale bar 40 mum). Horizontal bars indicate median. * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 BAFF-R expressing B cells at different maturational stages are present in decidua. To identify lymphocytes, in the first panel to the far left, live cells were gated using a viability dye that marks all dead cells and the lymphocyte gate was then set within CD45-expressing singlet leukocytes. (a - c) Within lymphocytes, CD56 + NK cells, CD3 + CD56 neg T cells, CD3 + CD56 + NK-T-like cells and CD19 + CD20 + B cells were identified (second and third panels). B cell maturational stages were distinguished based on CD24 and CD38 expression (fourth panel). The BAFF-R expression on the different lymphocyte populations is depicted to the far right. (d) The proportion of different cell subsets with in the lymphocyte gate and (e) the proportion of B cells at different maturational stages isolated from decidua basalis, decidua parietalis and cord blood. (f) The mean fluorescence intensity of BAFF on B cells at different maturational stages. Floating bars show minimum to maximum values, and horizontal bar indicates the median (n = 3). Approximately 40.000 cells were collected in the lymphocyte gate for d. basalis and CBMC and 20.000 for d. parietalis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 BAFF-R-positive cells are increased in NALT by IFN-alpha administration or age in NALT upon primary infection with RSV. BAFF-R-positive cells by flow cytometry in NALT and lungs from RSV-infected adult (AR) and neonatal mice receiving IFN-alpha (INR) or placebo (NR) 16 h before RSV infection and adult (ARR) and neonatal mice receiving IFN-alpha (INRR) or placebo (NRR) 16 h before RSV infection and reinfected 4 weeks after primary infection. ( a ) Representative flow cytometry panels of B220 + CD19 + BAFF-R + cells. ( b-f ) Percentage of B220 + CD19 + BAFF-R + cells at different time points. ( b ) 7 dpi; ( c ) 14 dpi; ( d ) 21 dpi; ( e ) 7 days post-secondary infection in NALT; ( f ) 7 days post-secondary infection in lungs. ( g ) IHC analysis demonstrating expression of BAFF-R protein in NALT and lungs of RSV-challenged groups and control mice at 7, 14, and, 21 days post infection, as well as, after reinfection. Magnification 200x; scale bar = 100 mum. n = 3-5; N = 2 * P < 0.05, ** P < 0.01.

16-9117-82

Antibody data